Know Cancer

forgot password

Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkin's Lymphoma

Phase 3
Not Enrolling
Non-Hodgkin's Lymphoma

Thank you

Trial Information

Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkin's Lymphoma

Rituxan is a mouse antibody that has been changed to make it similar to a human antibody.
Antibodies are proteins that can protect the body from foreign invaders, such as bacteria
and viruses, by binding to substances called antigens. Rituxan works by binding to a
protein, called the CD20 protein (which is found on the surface of normal and cancerous
B-lymphocytes). This binding may help to destroy the B-lymphocytes.

Before the study begins, you will have a physical exam, routine blood tests (1-2
tablespoons), and urine tests. Women who are able to have children must have a negative
blood pregnancy test. You will also have a chest x-ray and an ECG (test to measure the
electrical activity of the heart). The status of the lymphoma will be evaluated by bone
marrow biopsy. To collect a bone marrow sample, an area of the hip or chest bone is numbed
with anesthetic and a small amount of bone marrow is withdrawn through a large needle. CT
scans and gallium or PET scans will be performed. If you had lymphoma in other areas of your
body additional tests may be needed as determined by your treating physician. Tests to
evaluate the status of the lymphoma will be repeated before each cycle of chemotherapy. If
your white count is low you may need injections of NeupogenTM (growth factor) daily till
your white blood cell count is high enough to start the next round of treatment.

You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.
Participants in one group will receive rituximab. Participants in the other group will not
receive rituximab. There is an equal chance of being assigned to either group.

Treatment will start between 5-6 months after your stem cell transplant. If you are assigned
to the rituximab group, you will receive a total of 4 cycles of treatment. Each cycle will
be given 6 months apart. Each cycle is made up of 4 doses of rituximab given once a week for
4 weeks. If the disease returns or intolerable side effects occur while on treatment, you
will be taken off the study. You may still be able to receive rituximab outside of this
study if your treating physician decided that it is okay.

Treatment will be given on an outpatient basis. The treatment can be given at M. D. Anderson
or by your local cancer doctor. Patients who are assigned to the rituximab arm must be
willing to get their first and third cycle (all 4 doses) at M. D. Anderson, if their local
physician is unable to draw and ship samples to the central laboratory for rituximab levels.
Blood will be drawn (approximately one teaspoon) before and after the first and fourth dose
and before the second and third dose of those two treatment cycles. The treatment will be
given by vein over a period of several hours. Participants who have easily accessible veins
may get this treatment by having a temporary needle placed in the vein for the treatment.
For participants who do not have easily accessible veins, a central venous catheter (long
plastic tube - CVL) will be placed in a big vein of the arm or chest.

Participants who do not receive rituximab will be followed every 6 months at M. D. Anderson
as is standard of care.

All participants (even those who do not receive the rituximab) will have to return to M. D.
Anderson every 6 months for a period of 3 years (from the date of enrollment) to have the
lymphoma evaluated. The status of the lymphoma will be evaluated by blood tests (1-2
tablespoons), CT scans, PET or Gallium scans and bone marrow biopsy.

This is an investigational study. Rituximab has been approved by the FDA. About 90 patients
will take part in the study. All will be enrolled at M. D. Anderson.

Inclusion Criteria:

1. Patients with diffuse large B cell non-Hodgkin's lymphoma who are 5-6 months status
post an autologous stem cell transplant and are in CR. Patients who are positive for
t(14;18) by PCR or for BCL-2 by Southern blot are eligible provided there is no other
disease present.

2. Absolute neutrophil count (ANC) > 1500/mm3 independent of growth factor support

3. No evidence of symptomatic cardiac or pulmonary disease

4. Platelet count > 75,000 mm3

5. Zubrod performance status of 2 or less.

6. Negative pregnancy test in patients of "child bearing potential"

Exclusion Criteria:

1. Uncontrolled active infection

2. Severe concomitant medical or psychiatric illness

3. Serum bilirubin > 2.0 mg/dl 4) Transaminases > 2xULN 5) Serum creatinine > 2.0 mg/dl

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients with Progression Free Survival (PFS)

Outcome Time Frame:

2 Years

Safety Issue:


Principal Investigator

Chitra M. Hosing, MD

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

August 2003

Completion Date:

April 2010

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Rituximab
  • Rituxan
  • Lymphoma
  • High dose chemotherapy
  • Autologous transplantation
  • Autologous stem cell transplant
  • ASCT
  • Lymphoma
  • Lymphoma, Non-Hodgkin



UT MD Anderson Cancer CenterHouston, Texas  77030